AU2022322077A1 - Subcutaneous unit dosage forms - Google Patents

Subcutaneous unit dosage forms Download PDF

Info

Publication number
AU2022322077A1
AU2022322077A1 AU2022322077A AU2022322077A AU2022322077A1 AU 2022322077 A1 AU2022322077 A1 AU 2022322077A1 AU 2022322077 A AU2022322077 A AU 2022322077A AU 2022322077 A AU2022322077 A AU 2022322077A AU 2022322077 A1 AU2022322077 A1 AU 2022322077A1
Authority
AU
Australia
Prior art keywords
biologic
dose
unit dosage
efgartigimod
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022322077A
Other languages
English (en)
Inventor
Erik HOFMAN
Peter Ulrichts
Antoinetta Jacoba Maria VAN BRAGT
Peter Verheesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2022322077A1 publication Critical patent/AU2022322077A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2022322077A 2021-08-02 2022-08-02 Subcutaneous unit dosage forms Pending AU2022322077A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203856P 2021-08-02 2021-08-02
US63/203,856 2021-08-02
PCT/IB2022/000443 WO2023012515A2 (en) 2021-08-02 2022-08-02 Subcutaneous unit dosage forms

Publications (1)

Publication Number Publication Date
AU2022322077A1 true AU2022322077A1 (en) 2024-02-08

Family

ID=83192179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022322077A Pending AU2022322077A1 (en) 2021-08-02 2022-08-02 Subcutaneous unit dosage forms

Country Status (11)

Country Link
US (1) US20240325528A1 (https=)
EP (1) EP4380618A2 (https=)
JP (1) JP2024530152A (https=)
KR (1) KR20240040104A (https=)
CN (1) CN117897172A (https=)
AU (1) AU2022322077A1 (https=)
CA (1) CA3228105A1 (https=)
IL (1) IL310608A (https=)
MX (1) MX2024001631A (https=)
TW (1) TW202320849A (https=)
WO (1) WO2023012515A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
CN119365209A (zh) * 2022-04-26 2025-01-24 阿根思有限公司 用于使用fcrn拮抗剂治疗大疱性类天疱疮的方法
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
WO2025233684A1 (en) * 2024-05-10 2025-11-13 argenx BV Subcutaneous formulations, pre-filled syringes and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
SI4269578T1 (sl) 2008-03-06 2024-07-31 Halozyme, Inc. Sestava topne hialuronidaze
EA022752B1 (ru) 2008-12-09 2016-02-29 Галозим, Инк. Длинные растворимые полипептиды рн20 и их использование
HUE028832T2 (en) * 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
CA3081144A1 (en) * 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
KR102650991B1 (ko) 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
JP2023509195A (ja) * 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法

Also Published As

Publication number Publication date
WO2023012515A2 (en) 2023-02-09
IL310608A (en) 2024-04-01
WO2023012515A3 (en) 2023-04-06
CN117897172A (zh) 2024-04-16
KR20240040104A (ko) 2024-03-27
US20240325528A1 (en) 2024-10-03
TW202320849A (zh) 2023-06-01
JP2024530152A (ja) 2024-08-16
CA3228105A1 (en) 2023-02-09
MX2024001631A (es) 2024-04-19
EP4380618A2 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
US20240325528A1 (en) Subcutaneous unit dosage forms
AU2017265049B2 (en) Anti-VLA1 (CD49A) Antibody Pharmaceutical Compositions
US20250195649A1 (en) High Concentration Bispecific Antibody Formulations
TR201808801T4 (tr) İmmünoglobulin formülasyonu ve bunun hazırlanış yöntemi.
TW201709927A (zh) 使用ＡＣＴＲＩＩ配位體捕捉以治療β－地中海型貧血
EP3043774A2 (en) Liquid protein formulations containing ionic liquids
EP4243928B1 (en) Anti-gdf15 antibody and a dosage regimen for the treatment of cancer
EP3868785A1 (en) Anti-cd28 humanized antibodies formulated for administration to humans
KR20250109193A (ko) Fcrn 길항제를 사용하여 루푸스 신염을 치료하는 방법
CN118105512A (zh) 含有hGH融合蛋白的治疗生长激素缺乏症的药物组合物
WO2021147854A1 (zh) 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途
US20250352617A1 (en) Taci-fc fusion protein liquid pharmaceutical preparation
US20240034813A1 (en) High Concentration Bispecific Antibody Formulations
HK40104320A (zh) 皮下单位剂型
WO2025029873A9 (en) Treatment of hair-loss disorder
WO2025224506A1 (en) Methods for reducing platelet degradation using fcrn antagonists
WO2025179012A1 (en) Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens
HK40119812A (en) Taci-fc fusion protein liquid pharmaceutical preparation
NZ717918B2 (en) Liquid protein formulations containing ionic liquids